The partnership is the first corporate-sponsored research jointly undertaken by Sanford-Burnham and TRI. Advanced technologies, including genomic and metabolite profiling, will be used to identify metabolic signatures, genes and pathways that could serve as biomarkers, and novel drug targets aimed at developing more personalized treatments for obesity and its complications. The research model combines laboratory research with detailed investigations of patient cohorts so that scientists can compare data from experimental models and humans to identify genetic and metabolomic matches.
“This research partnership is a collaborative model that capitalizes on the synergistic expertise of each group and provides all partners with access to our Cardiometabolic Phenotyping, Metabolomics and Genomics technology cores,” says Daniel P. Kelly, MD, scientific director, Sanford-Burnham Medical Research Institute. “It offers much promise for expediting new drug candidates into Takeda’s development pipeline.”
The two-year collaboration includes research funding from Takeda divided between Florida Hospital-TRI and Sanford-Burnham. Takeda executives say the collaboration represents one of the largest discovery research partnerships that it has conducted with the not-for-profit sector.
“We view this collaboration as an opportunity to further Takeda’s goal of identifying targets for new therapeutics to treat obesity and its negative health consequences, including metabolic syndrome, diabetes, and heart disease.” says Paul Chapman, general manager, head of Pharmaceutical Research Division of Takeda.
The partners say the agreement will set the stage for future collaborative drug discovery campaigns aimed at novel therapeutics to treat obesity.